Print Page   |   Contact Us   |   Sign In   |   Join
Business Wire Life Sciences News (US)
Share |

Dassault Systèmes’ Living Heart Project Reaches Next Milestones in Mission to Improve Patient CareOpen in a New Window

HOLLYWOOD, Fla.--(BUSINESS WIRE)--Dassault Systèmes (Paris:DSY) (Euronext Paris: #13065, DSY.PA) today outlined, at the 3DEXPERIENCE Forum North America, multiple milestones in its Living Heart Project aimed to drive the creation and use of simulated 3D personalized hearts in the treatment, diagnosis and prevention of heart diseases. As the scientific and medical community seeks faster and more targeted ways to improve patient care, the Living Heart Project is extending its reach through new pa

 

Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung CancerOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced updated results from its clinical trials, including the STARTRK-2 trial, of entrectinib - an investigational, CNS-active, potent, and selective tyrosine kinase inhibitor being developed for tumors that harbor NTRK fusions or ROS1 fusions. In this interim analysis, entrectinib demonstrated a 78% confirmed ORR (by Investigator; 95% CI: 60.0, 90.7) and a 69% c

 

Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in JapanOpen in a New Window

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer

 

Intermountain Healthcare Announces Precision Health Research Endeavors with 10x GenomicsOpen in a New Window

PLEASANTON, Calif. & ST. GEORGE, Utah--(BUSINESS WIRE)--#ASHG17--Intermountain Healthcare Announces Precision Health Research Endeavors with 10x Genomics

 

RenovaCare, Inc. Closes Registered Direct Offering and Concurrent Private PlacementOpen in a New Window

NEW YORK & PITTSBURGH & BERLIN--(BUSINESS WIRE)--RenovaCare, Inc., (OTCQB:RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately 915,000 shares of common stock in a registered direct offering and common stock purchase warrants in a concurrent private placement. The offerings are

 

‘Keeping the Promise—AHF 30 Years’Open in a New Window

LOS ANGELES--(BUSINESS WIRE)--‘Keeping the Promise—AHF 30 Years’ - Documentary film screening & reception Thurs., Oct. 19 at Hollywood’s historic Arclight Cinerama Dome Theater

 

AgModels, Cornell Cooperative Extension and The New York City Watershed Agricultural Program Team Up to Help Dairy Farms and the EnvironmentOpen in a New Window

SYRACUSE, N.Y.--(BUSINESS WIRE)--AgModels, Cornell Coop. Extension and NYC Watershed Program make Precision Feed Management Tool Available Online to Help Dairy Farms & Water Quality

 

Most Energy Efficient Performance in Ultra-Low Temperature Technology on Exhibit at I2SL, BostonOpen in a New Window

WOOD DALE, Ill.--(BUSINESS WIRE)--#I2SL--ENERGY STAR® Certified, 25.7 cu.ft. -86°C freezer on display at I2SL, Boston, illustrates most energy efficient ULT freezer technology.

 

IntriCon to Announce 2017 Third-Quarter Results on Monday, November 6Open in a New Window

ARDEN HILLS, Minn.--(BUSINESS WIRE)--IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn devices, today announced that it will release its 2017 third-quarter results on Monday, November 6, 2017, at market close. Following the release, the company will hold an investment community conference call on the same day, beginning at 4:00 p.m. CT. Mark Gorder, president and chief executive officer, and Scott Longval, chief financial officer, will review t

 

BioTime, Inc. Announces Closing of Public Offering and Underwriters’ Full Exercise of Over-Allotment OptionOpen in a New Window

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced public offering of 9,615,385 shares of common stock, including 1,442,308 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The offering price to the public was $2.60 p

 

Bovie Medical Corporation to Release Third Quarter 2017 Financial Results on November 2, 2017Open in a New Window

CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical (NYSE American: BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the third quarter of 2017 will be released after the market closes on Thursday, November 2. Management will host a conference call at 4:30 p.m. Eastern Time on November 2 to discuss the results of the quarter and host a question and answer session. To listen to the call by phone,

 

As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including TruvadaOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada

 

Exomedicine Institute Appoints Pam Platt as Chief StorytellerOpen in a New Window

LEXINGTON, Ky.--(BUSINESS WIRE)--Veteran journalist Pam Platt joins Exomedicine Institute as Chief Storyteller to share stories emerging from new field of medical research in space.

 

Walgreens to Establish New Technology Center of Excellence in the Sullivan CenterOpen in a New Window

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens today announced with Chicago Mayor Rahm Emanuel that it will bring approximately 300 technology positions to its current downtown Chicago office in the Sullivan Center to establish a new technology center of excellence. Through a combination of new hires and relocations from its Deerfield, Ill., support office, Walgreens will double its number of employees working at the Sullivan Center, located at 36 S. Wabash Ave. Walgreens is currently building out

 

Trends Spotlight: Three Areas of Focus to Reduce CLABSIsOpen in a New Window

NORTHFIELD, Ill.--(BUSINESS WIRE)--CEO of the Association for Vascular Access (AVA) discusses trends the organization recognizes will help reduce readmissions.

 

DebMed Offers Guidance for Improving Hand Hygiene Compliance in Healthcare Facilities in Recognition of International Infection Prevention Week, Oct. 15-21Open in a New Window

CHARLOTTE, N.C.--(BUSINESS WIRE)--In honor of International Infection Prevention Week, DebMed is offering tips to improve hand hygiene compliance within healthcare facilities.

 

Derek Griffith Named Executive Vice President of Store OperationsOpen in a New Window

CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid Corporation (NYSE: RAD) today announced that Derek Griffith, Rite Aid’s current senior vice president of operations in the Northeast and Midwest, has been named executive vice president of store operations. In this position, Griffith will be responsible for all aspects of the company’s chainwide store operations. He will report to Bryan Everett, chief operating officer of Rite Aid stores. “Derek is a seasoned retail operator with demonstrated expertise

 

Dr. David Walt of Wyss Institute to Speak at Powering Precision Health 2017Open in a New Window

BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#PPH--Powering Precision Health 2017, the nation’s first precision health summit, announces Dr. David Walt will speak at the summit on October 24th.

 

Battelle, Rare Earth Salts Team on Department of Energy ProjectOpen in a New Window

COLUMBUS, Ohio & BEATRICE, Neb.--(BUSINESS WIRE)--Battelle is teaming with Rare Earth Salts (RES) on a potentially groundbreaking project for the United States Department of Energy’s National Energy Technology Laboratory. The project, Recovery of High Purity Rare Earth Elements (REEs) from Coal Ash via a Novel Separations Process, will produce valuable Rare Earth Oxides from coal fly ash, converting them to the high purities necessary for a saleable product. The two organizations will advance t

 

AskBio and Columbus Venture Partners Launch Gene Therapy Company ViralgenOpen in a New Window

CHAPEL HILL, N.C.--(BUSINESS WIRE)--AskBio Pharmaceuticals and Columbus Venture Partners Launch Gene Therapy Company Viralgen

 

McKesson Partners with Lyft to Support California Wildfire VictimsOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--To help support the transportation needs of individuals and families affected by the wildfire in the Northern California area, McKesson has partnered with Lyft to provide complimentary rides to local hospitals or treatment centers. Today’s partnership follows on McKesson’s donation of $100,000 to the American Red Cross in support of wildfire relief efforts. “Because of the North Bay fires, even getting to treatment centers remains a challenge for many patients. T

 

Median Technologies to Attend The Liver Meeting® of The American Association for the Study of Liver Diseases to Be Held October 20-24, 2017 in Washington, DC, USAOpen in a New Window

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT), the Imaging Phenomics Company®, announced today that it will participate in The Liver Meeting®, the annual meeting of the Association for the Study of Liver Diseases (AASLD) October 20-24 at the Walter E. Washington Convention Center, Washington DC, USA. The industry exhibition will be opened from Oct 21st to Oct. 23rd. The company’s scientific and business team will demonstrate Median’s imaging pheno

 

Mauna Kea Technologies Appoints Olivier Regnard as Deputy CEO And Chief Financial OfficerOpen in a New Window

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer, effective immediately. Mr. Regnard brings nearly 20 years of finance, accounting and operational experience to the Company and already has familiarity with Mauna Kea Technologies, hav

 

Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis BOpen in a New Window

STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, will be presenting a poster on TG1050 first promising clinical results at the American Association for the Study of Liver Diseases (AASLD) Meeting 2017, in Washington, DC, October 20-24. TG1050 is a therapeutic vaccine, that is currently being evaluated in an international first-in-man Phase 1/1b trial in patients with chroni

 

The Allen Institute of Artificial Intelligence (AI2) Adds Over 30 Million Biomedical Papers to Semantic Scholar to Help the Medical Community Fight Information Overload and Save LivesOpen in a New Window

SEATTLE--(BUSINESS WIRE)--The Allen Institute for Artificial Intelligence (AI2) today announced its AI-based academic search engine, Semantic Scholar, has made significant progress with the addition of tens-of-millions of biomedical papers. Semantic Scholar enables deep information extraction and entity linking to create a scientific knowledge graph out of the insights buried in millions of documents. Semantic Scholar now covers neuroscience, computer science and biomedical papers and is tracki

 

Powering Precision Health 2017 Announces World-Renowned Keynote LineupOpen in a New Window

BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#CTE--Powering Precision Health 2017, the nation’s first precision health summit, today announced its lineup of world-renowned featured keynoters.

 

SwRI Expands Automotive Research Footprint with Laboratory in Ann ArborOpen in a New Window

SAN ANTONIO--(BUSINESS WIRE)--Test cells improve support for Detroit-area clients

 

Cleveland Clinic Joins PierianDx’s Customer Network to Accelerate Precision MedicineOpen in a New Window

ST. LOUIS--(BUSINESS WIRE)--Cleveland Clinic chooses PierianDx platform to accelerate precision medicine.

 

Life Spine to Showcase Micro Invasive Expandable Technology at NASS Annual MeetingOpen in a New Window

HUNTLEY, Ill.--(BUSINESS WIRE)--Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that it will be participating in the 32nd North American Spine Society (NASS) Annual Meeting, taking place in Orlando, October 24-27th, 2017. The meeting is expected to attract over 3,000 surgeons and other healthcare professionals from across the globe. Life Spine is excited to showcase its Procedural Solu

 

Attune Medical Closes $10 Million Series C Financing To Support Continued Global Adoption of Esophageal Temperature Management DeviceOpen in a New Window

CHICAGO--(BUSINESS WIRE)--Breakthrough medical device firm Attune Medical has closed a $10 million Series C financing.

 

M3 Biotechnology Launches Clinical Trials for Alzheimer’s Disease Drug Focused on Restoring Lost Connections in the BrainOpen in a New Window

SEATTLE--(BUSINESS WIRE)--#Alzheimers--M3 Biotechnology starts clinical trials of new drug expected to slow or stop Alzheimer's disease progression as indicated by pre-clinical studies.

 

Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)Open in a New Window

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with IBS-C

 

An Analysis of the 2018 Medicare Advantage Competition by Mark Farrah AssociatesOpen in a New Window

MCMURRAY, Pa.--(BUSINESS WIRE)--Mark Farrah Associates presents a snapshot of the 2018 Medicare Advantage market.

 

Partners North Pharmacy Uses statDISPENSE to Enhance Control of Emergency Medication KitsOpen in a New Window

LOUISVILLE, Ky.--(BUSINESS WIRE)--Partners North Pharmacy, located in Shreveport, Louisiana has recently implemented Creative Strategies’ statDISPENSE technology to automate manual emergency and first-dose kits for eight of its skilled nursing facility clients. statDISPENSE is a smart padlock technology that turns traditional emergency medicine kits, or “tackle box” exchange systems, into a fully automated dispensing and tracking system that integrates medical record keeping and inventory manag

 

Cydan Raises $34 Million to Accelerate New Treatments for Rare Genetic DiseasesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan announced a new round of financing, raising a committed $34 million to advance the company’s mission to create new treatments for rare diseases.

 

Jay Flatley and John Martin to be Named Recipients of Life Sciences Leadership Award at California Life Sciences Association’s 2017 Pantheon DiNA™ AwardsOpen in a New Window

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--#CLSAPantheon--Jay Flatley & John Martin to be Named Recipients of Life Sciences Leadership Award at California Life Sciences Association’s 2017 #CLSAPantheon

 

Health Mart® Showcases Solutions for Clinical and Financial Performance at NCPAOpen in a New Window

ORLANDO, Fla.--(BUSINESS WIRE)--Health Mart® Showcases Solutions for Clinical and Financial Performance at NCPA

 

OncLive® Adds George Washington Cancer Center to its Strategic Alliance Partnership ProgramOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--OncLive® Adds George Washington Cancer Center to its Strategic Alliance Partnership Program

 

Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation RecoveryOpen in a New Window

BELPRE, Ohio--(BUSINESS WIRE)--ProtoKinetix Scientific Update

 

PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight CancerOpen in a New Window

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--#breakthroughtechnology--PharmaCyte announced it has identified an organism to activate a cannabinoid prodrug into its active cancer-killing form.

 

Allurion Technologies Appoints Four Distinguished Board Members; Secures Term Loan from Silicon Valley BankOpen in a New Window

NATICK, Mass.--(BUSINESS WIRE)--#allurion--Allurion Technologies Appoints Four Distinguished Board Members; Secures Term Loan from Silicon Valley Bank

 

SessionM Hires Amelio Vázquez-Reina to Lead Its Data Science, AI and Machine Learning DivisionOpen in a New Window

BOSTON--(BUSINESS WIRE)--SessionM, the leading customer engagement platform, today announced that it has hired Amelio Vázquez-Reina as vice president of data science, artificial intelligence (AI) and machine learning. In this role, Vázquez-Reina will work closely alongside the data engineering team to lead strategic implementation of new AI solutions into the company’s platform. Vázquez-Reina joins SessionM from DataXu, where he drove scale and revenue through the development and application of

 

Masimo to Report Third Quarter 2017 Financial Results after Market Close on Tuesday, October 31Open in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that it will release financial results for the third quarter ended September 30, 2017, after the market closes on Tuesday, October 31, 2017. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer, along with Mark de Raad, the company’s retiring CFO. A live w

 

IEEE Releases Findings from First Detailed Study of Blockchain Adoption in the Pharmaceutical EnterpriseOpen in a New Window

PISCATAWAY, N.J.--(BUSINESS WIRE)--IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE-SA), today announced the upcoming publication of a report entitled: The State of Blockchain Adoption on the Pharmaceutical Supply Chain. The independent study, a first-of-its-kind, examines the barriers and perceived benefits of adopting the technology with insights from industry executives currently exploring u

 

Smiths Medical to Introduce Innovative New Products and Host Symposium at Anesthesiology 2017 Annual MeetingOpen in a New Window

MINNEAPOLIS--(BUSINESS WIRE)--Smiths Medical, a leading global medical device manufacturer, will introduce several innovative new products at the upcoming American Society of Anesthesiologists annual meeting in Boston, Massachusetts on October 21-23. New Products The Invasive Blood Pressure Monitoring System meets the challenging needs of critical patients with a sophisticated product that helps clinicians focus on patient care. The aerFree™ Airway Management System is the first FDA-cleared ext

 

Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension (PAH)Open in a New Window

SUNNYVALE, Calif.--(BUSINESS WIRE)--Reviva Pharmaceuticals, Inc. (Reviva), a privately held, clinical stage pharmaceutical company developing innovative next generation therapeutics for the treatment of CNS, cardiopulmonary and metabolic diseases, today announced that it has successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound RP5063, which is being developed for the treatment of pulmonary arte

 

Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology TherapeuticsOpen in a New Window

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development. Dr. Riva will become a member of Gilead’s senior leadership team. Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutic Area Head. He has been instrumental

 

Quidel Receives FDA Clearance for Its Solana® RSV + hMPV AssayOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received clearance from the United States Food and Drug Administration (FDA) to market its Solana® respiratory syncytial virus (“RSV”) + human metapneumovirus (“hMPV”) Assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and

 

Concentric Analgesics Names Thomas B. King to Board of DirectorsOpen in a New Window

LOS ALTOS, Calif.--(BUSINESS WIRE)--Concentric Analgesics Appoints Thomas B. King to Board of Directors; Company Launches New Program in Osteoarthritis Pain

 

Agilent Expands SureGuide Portfolio with CRISPR-based Products to Accelerate Disease ResearchOpen in a New Window

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the first expansion of the SureGuide pooled CRISPR libraries for functional genomics, offering pooled libraries for CRISPR activation and interference (CRISPR a/i). The announcement was made at the at the American Society for Human Genetics Conference (ASHG), being held October 17 - 21 in Orlando, Florida. Every SureGuide CRISPR library is synthesized using Agilent’s advanced SurePrint DNA synthesis platfo

 

Scientist.com and VWR Collaborate to Create an End-to-End Online Research SolutionOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--#fasterscience--Scientist.com, the leading global online marketplace for research services, today announced its collaboration with VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers. VWR customers in the U.S. can now purchase thousands of custom products and research services through The VWR Science portal powered by Scientist.com. “We are excited to offer this unique solution that enables our customers

 

Wiley Announces Brian A. Napack as President and CEOOpen in a New Window

HOBOKEN, N.J.--(BUSINESS WIRE)--John Wiley and Sons, Inc. (NYSE:JWA) (NYSE:JWB), a global research and learning company and one of the world’s leading publishers, today announced that Brian A. Napack has been named its new President and CEO, effective December 4. Mr. Napack succeeds Matthew Kissner, who has served as interim CEO since May of 2017. Mr. Kissner, a 14-year veteran of Wiley’s Board of Directors, will remain as Chairman. “I am delighted to introduce Brian Napack as the 14th CEO in W

 

GenePeeks Expands Distribution to India with Exclusive Agreement with CORE DiagnosticsOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GenePeeks announced an exclusive distribution agreement with CORE Diagnostics of India to deliver preconception screening technology.

 

Adventist Health System Partners with Glytec to Enhance Diabetes CareOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--#A1C--Adventist Health System, headquartered in Altamonte Springs, Florida, will implement Glytec’s diabetes therapy management software at 39 hospitals.

 

Air Techniques Donates to the University of Puerto Rico School of Dental MedicineOpen in a New Window

MELVILLE, N.Y.--(BUSINESS WIRE)--Air Techniques has donated several boxes of their Monarch brand of Hand Sanitizer to the University of Puerto Rico School of Dental Medicine.

 

Myomo, Inc. Launches Awareness Program for Veterans of the U.S. Armed ForcesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical device company, today announced the launch of MyoPro For Veterans, a strategic awareness program that broadens accessibility of MyoPro powered upper limb orthotics (arm brace) to the many veterans of the U.S. Armed Forces that could potentially benefit from the technology, restoring function to weakened or paralyzed upper limbs. “The U.S. Veterans Administration includes 16

 

Eagle Pharmaceuticals Announces New Patent for RYANODEXOpen in a New Window

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) today announced that the Company has been issued a new patent related to its RYANODEX® formulation (dantrolene sodium) by the United States Patent and Trademark Office (USPTO). Patent number 9,789,090 will expire in June 2022. The USPTO has now issued seven patents in the RYANODEX family of patents expiring from 2022 to 2025. The ‘090 patent is directed to a method of treating non-normoth

 

Sema4 Announces Collaboration With California Cryobank to Improve and Expand Genetic Screening for Sperm DonorsOpen in a New Window

STAMFORD, Conn.--(BUSINESS WIRE)--#GeneticTesting--Sema4 is collaborating with California Cryobank to bring comprehensive genetic screening to new Cryobank sperm donors.

 

Southern Spine Announces “Clinical and Biomechanical Advantages of Interspinous Process Fixation: A Review”Open in a New Window

MACON, Ga.--(BUSINESS WIRE)--Southern Spine Literature Review

 

Second Sight Receives Approval from Bundesinstitut für Arzneimittel und Medizinprodukte in Germany to Begin Study to Implant and Evaluate Argus II in Better-Sighted Retinitis Pigmentosa PatientsOpen in a New Window

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received approval from Bundesinstitut für Arzneimittel und Medizinprodukte (“BfArM”), the German competent authority, and a favorable opinion by the applicable ethics committees, to begin a 10-patient study in Germany to implan

 

Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver DiseasesOpen in a New Window

OSAKA, Japan & CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH). “The ability to study pathophysiology in a human multi-cell system is crucial for our understanding of disease and how to develop best-in-class therapies,” said Gareth Hicks, Ph.D.,

 

Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of PsoriasisOpen in a New Window

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis

 

US FDA Accepts Supplemental Biologics License Application for IMFINZI® (durvalumab) in Locally Advanced, Unresectable Non-Small Cell Lung CancerOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) for the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy. The FDA has granted IMFINZI Priority Review statu

 

Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic DiseasesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, today announced that it has completed a $42.5 million Series A financing to advance multiple programs into the clinic. Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A, and also invested in seed financing in 2016. Gemini is developing first-in-class therapeutics built on the stro

 

Verastem Pays Milestone Payment to Infinity PharmaceuticalsOpen in a New Window

BOSTON, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced payment of a $6 million milestone to Infinity Pharmaceuticals, Inc., representing the first milestone under the duvelisib license agreement between Verastem and Infinity. This milestone is based on the achievement of positive top-line results from the Phase 3 DUO™ study evaluating the efficacy and safety of duve

 

Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid TumorsOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation for entrectinib in the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapy. Through the PRIME initiative, Igny

 

Eos Biosciences Announces Issuance of Additional U.S. Patent For Targeted Breast Cancer TherapyOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--Eos Biosciences announces issuance of second U.S. Patent for its targeted breast cancer therapy, a HER3-targeted Eosome with doxorubicin payload.

 

Vertex Announces 10-Year, $500 Million Corporate Giving CommitmentOpen in a New Window

BOSTON--(BUSINESS WIRE)--BOSTON – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced a 10-year, $500 million corporate giving commitment.

 

Windham Group Receives First Case in Massachusetts’s Alternate Opioid Treatment Pathway ProgramOpen in a New Window

BOSTON--(BUSINESS WIRE)--The Windham Group workers' compensation case management company receives first case in Massachusetts's Alternate Opioid Treatment Pathway program.

 

Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller UniversityOpen in a New Window

BOSTON--(BUSINESS WIRE)--Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University

Abbott

BioFlorida, Inc. | 6742 Forest Hill Blvd., Suite 256 | West Palm Beach, FL 33413
(P) 561-653-3839 admin@bioflorida.com
Membership Management Software Powered by YourMembership  ::  Legal